GLP-1 medications drive R$ 27 billion market shift in Brazil

The rise of GLP-1 medications, such as semaglutide and tirzepatide, is driving significant economic and behavioral shifts in Brazil. The market for these weight-loss drugs is estimated at approximately R$ 27 billion. Formal sales reached R$ 14.6 billion between May 2025 and April 2026, representing a 110% increase, while Itaú BBA projects an unmonitored market of R$ 12.5 billion for the same period.

This pharmaceutical trend is reshaping consumer habits across various sectors. In supermarkets, there is a noted decline in the consumption of processed foods, chocolates, and alcoholic beverages, alongside increased demand for proteins, fruits, vegetables, and supplements. The beverage industry is also seeing growth in low-calorie and non-alcoholic options. Additionally, the phenomenon is impacting the fashion industry through demand for smaller clothing sizes and stimulating the beauty and fitness sectors.

However, the rapid expansion has introduced public health risks. The proliferation of counterfeit products and informal sales channels poses threats regarding storage failures and unknown compositions. Organizations like Abrafarma emphasize the necessity of regulated pharmacies and professional pharmaceutical guidance to ensure patient safety and combat the risks associated with smuggled or unregulated medications.